The study reveals the impact of a dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability.
The transaction creates increased clinical and economic value for 11,500 specialty providers, including more than 7,000 physicians across 1,200 independent physician practices